Verify any claim · lenz.io
Claim analyzed
Health“As of April 2026, treatment advances have made multiple myeloma nearly a curable disease.”
The conclusion
Treatment advances in multiple myeloma are real and significant, but the claim that the disease is "nearly curable" materially overstates the medical consensus as of April 2026. The most authoritative sources — including Memorial Sloan Kettering (January 2026) and Indiana University Cancer Center — explicitly state myeloma remains incurable. Cure-like outcomes such as deep remission and MRD negativity apply only to specific patient subsets under specific regimens, and relapse remains common across the broader population.
Based on 11 sources: 5 supporting, 1 refuting, 5 neutral.
Caveats
- The medical consensus as of early 2026 still classifies multiple myeloma as incurable; leading cancer centers explicitly state this.
- Cure-like outcomes (functional cure, MRD negativity, PFS plateaus) apply only to specific patient subsets under specific treatment protocols — not the general myeloma population.
- The claim commits a composition fallacy by extrapolating promising subset results to characterize the entire disease as 'nearly curable,' omitting that relapse remains common even after deep remission.
This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.
Sources
Sources used in the analysis
Multiple myeloma is currently not curable, but we can manage the disease effectively for years. Treatments can bring the disease into remission, but it often returns. New drugs developed over the past two decades have significantly improved prognosis.
Some of the treatment options for multiple myeloma that Mount Sinai researchers have been investigating are truly making a significant difference, with some coming close to being considered a cure, said Sundar Jagannath, MBBS. The development of CAR T cell therapies and bispecific antibodies is making curing multiple myeloma possible for the first time.
Years ago, clinicians had few options beyond melphalan and steroids to treat multiple myeloma. Today, that situation has changed substantially, with new therapy approvals coming fast and furious. And with advances in CAR T-cell and bispecific therapies, patients are living longer and having improved quality of life.
A 2024 study suggested that newer treatments are leading to deeper, long-lasting remissions — and even the possibility of a “practical cure” for some people. This means their myeloma remains undetectable and doesn't require ongoing treatment. However, current tests can't always detect tiny amounts of cancer. This is why doctors often say myeloma is in remission rather than cured, even if no cancer is found.
A single infusion of AZD0120 resulted in early and deep responses, with 96% ORR, 78% sCR/CR, and 94% MRD negativity in heavily pretreated patients with relapsed/refractory multiple myeloma. The median overall survival (OS) was clinically meaningful in older and younger patients who were treated with ide-cel; the median values were not reached (NR) and 39.5 months (95% CI, 27.8-NR), respectively.
While the disease has traditionally been considered incurable, advances in treatment are helping patients live longer, and in some cases, even reach long term remission. Now, with the therapies we have available, we are able to significantly modify the disease course, extend survival and, in some cases, transform this into more of a chronic condition.
A long-term follow-up study has found that up to one-third of patients with newly diagnosed multiple myeloma (MM) may achieve long-term survival through early “total therapy” protocols, demonstrating the lasting impact of immunomodulatory drugs and proteasome inhibitors. The estimated cure fraction, based on relative survival, rose from 20% in TT 1, to 37% with thalidomide in TT 2, and 43% with the addition of bortezomib in TT 3A.
Multiple myeloma isn't yet considered curable, but IU researchers are pushing to extend periods of remission for some patients and a minimal effect on quality of life. In other words, a “functional cure.”
In the PFS cure, there was a plateau phase from month 6, indicating that some patients could be potentially or functionally cured with this combination. Of course, this significant benefit in PFS translated into a benefit of OS, with 83% of the patients alive at 3 years.
A new treatment called the DKRd regimen is now the standard care. The ADVANCE clinical trial showed great results, with 59% of patients getting to MRD negativity. This is a big win for better patient outcomes and longer lives. Immunotherapies are redefining treatment options for multiple myeloma patients. Advancements in treatment are expected to improve myeloma survival rates.
The year 2026 brings new promise in multiple myeloma with a wide variety of treatment options available for both newly diagnosed and relapsed/refractory patients. Dr. Robert Orlowski will review advances in CAR T therapies, bispecific antibodies, targeted therapies, combination approaches and clinical trials to watch as the research continues advancing at a rapid pace in myeloma.
What do you think of the claim?
Your challenge will appear immediately.
Challenge submitted!
Expert review
How each expert evaluated the evidence and arguments
Expert 1 — The Logic Examiner
The pro side infers “nearly curable” from evidence of deep responses/MRD negativity, PFS plateaus, and discussion of “functional/practical cure” in subsets (Sources 2,5,7,9,4,8), but that chain overextends because these are either subset/early-surrogate signals or explicitly framed as possible/functional rather than establishing that the disease overall is close to being curable. Given multiple sources explicitly stating myeloma is still not considered curable as of early 2026 and is often managed as a chronic/relapsing condition (Sources 1,8,6,4), the claim's broad characterization (“treatment advances have made multiple myeloma nearly a curable disease”) is not logically supported and is best judged misleading rather than true.
Expert 2 — The Context Analyst
The claim uses the phrase "nearly a curable disease" without qualification, implying broad applicability, but the evidence consistently shows that cure-like outcomes apply only to specific subsets of patients — not the general myeloma population. The most authoritative and clearly dated source (MSK, January 2026) explicitly states myeloma "is currently not curable," Source 8 (IU Cancer Center) confirms it "isn't yet considered curable," and Source 6 frames the best realistic outcome as a "chronic condition." While Sources 2, 4, 7, and 9 do discuss "functional/practical cure" possibilities and rising cure fractions in select subgroups (up to 43% in total-therapy protocols), these are subset outcomes under specific regimens, not a population-wide near-cure status — and Source 4 explicitly warns that even undetectable disease is not called "cured" due to test limitations. The claim omits the critical context that these advances benefit only certain patient subgroups, that relapse remains common, and that the medical consensus as of April 2026 still does not classify multiple myeloma as nearly curable; the overall impression created by the unqualified claim is therefore misleading, even though the underlying treatment progress is real and significant.
Expert 3 — The Source Auditor
The most authoritative source in this pool — Source 1 (Memorial Sloan Kettering Cancer Center, January 2026, high authority) — explicitly and unambiguously states that "multiple myeloma is currently not curable," a position corroborated by Source 8 (Indiana University Comprehensive Cancer Center, November 2025, moderate authority), which confirms it "isn't yet considered curable," and Source 6 (Loma Linda University Health, March 2026), which frames the best-case scenario as transforming myeloma into "more of a chronic condition." Supporting sources are weaker in authority or carry important caveats: Source 2 (Mount Sinai) has no publication date, undermining its reliability; Sources 5 and 9 (CancerNetwork) report promising subset data but are a specialty trade publication, not primary research institutions; Source 7 (EMJ) discusses a rising "cure fraction" in select protocol subgroups, not the general patient population; and Sources 4, 10, and 11 are a patient community site, a private hospital, and a YouTube video respectively — all low-authority. The claim that myeloma is "nearly a curable disease" as of April 2026 is not supported by the most reliable, independent, and current sources, which consistently describe it as an incurable but increasingly manageable condition, with cure-like outcomes limited to subsets and framed aspirationally rather than as an established clinical reality.
Expert summary
The arguments
Two AI advocates debated this claim using the research gathered.
Argument for
By April 2026, multiple independent clinical and academic reports indicate that modern immunotherapies (CAR T cells and bispecific antibodies) are producing deep, durable responses consistent with a “functional/practical cure” in a meaningful subset of patients—e.g., Mount Sinai explicitly states curing multiple myeloma is now possible for the first time (Source 2), CancerNetwork reports MRD-negativity rates as high as 94% after a single infusion in heavily pretreated disease (Source 5), and a progression-free survival plateau suggesting potential/functional cure with teclistamab combinations (Source 9). This convergence—alongside long-term follow-up data estimating a rising “cure fraction” up to 43% with modern total-therapy-era regimens (Source 7) and mainstream discussions of “functional cure” and long-lasting treatment-free remission (Sources 4 and 8)—supports the characterization that treatment advances have made multiple myeloma nearly a curable disease, even if some leading centers still describe it as not universally curable at the population level (Source 1).
Your reliance on Source 2 (Mount Sinai) is critically undermined by the fact that it carries no publication date — making it impossible to verify its currency or credibility — and its claim that a cure is "now possible for the first time" is directly contradicted by the most authoritative and clearly dated source in the brief, Source 1 (Memorial Sloan Kettering Cancer Center, January 2026), which unambiguously states myeloma "is currently not curable." Furthermore, you commit a fallacy of composition by extrapolating subset outcomes — MRD-negativity rates in Source 5 and a "cure fraction" in Source 7 — to the entire disease population, when Source 4 explicitly warns that current tests cannot reliably detect residual cancer and Source 8 confirms the disease "isn't yet considered curable," meaning these promising statistics describe exceptional subgroups, not a near-universal cure that would justify the claim.
Argument against
The claim that multiple myeloma is "nearly curable" as of April 2026 is directly contradicted by the most authoritative source in the research brief: Source 1 (Memorial Sloan Kettering Cancer Center) explicitly states that "multiple myeloma is currently not curable," noting that while treatments can bring the disease into remission, "it often returns" — a fundamental characteristic incompatible with any reasonable definition of "nearly curable." Further undermining the claim, Source 8 (Indiana University Melvin and Bren Simon Comprehensive Cancer Center) confirms that myeloma "isn't yet considered curable," Source 6 (Loma Linda University Health) characterizes the best-case outcome as transforming it into "more of a chronic condition," and Source 4 (MyMyelomaTeam) acknowledges that even when no cancer is detected, doctors still refuse to use the word "cured" — collectively demonstrating that the medical consensus as of April 2026 firmly rejects the characterization of multiple myeloma as nearly curable.
You're committing an equivocation fallacy by treating “not universally curable” and clinicians' caution about using the word “cure” as proof that myeloma cannot be “nearly curable” in the functional/practical sense—yet Source 4 explicitly describes a “practical cure” (treatment-free, undetectable disease) for some people, and Source 8 frames the field's goal as a “functional cure,” which is exactly what “nearly curable” denotes. More importantly, your appeal to Source 1's population-level statement ignores the countervailing clinical signals of cure-like durability in subsets—Mount Sinai says curing myeloma is now possible with CAR T/bispecifics (Source 2), long-term follow-up estimates a rising “cure fraction” up to 43% (Source 7), and a PFS plateau with teclistamab combinations suggests potential/functional cure (Source 9)—so “consensus firmly rejects” is an overreach unsupported by the brief.